Stock of the Day

November 2, 2021

Legend Biotech (LEGN)

$21.13
+$0.35 (+1.7%)
Market Cap: $4.09B

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Today's Trend

Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) has seen mixed investor signals. The stock initially increased after a stronger-than-expected second-quarter report, but concerns about leadership changes, competition and sharply reduced price targets have weighed on sentiment.

  • Quarterly results exceeded expectations: Legend reported second-quarter EPS of $0.09 versus the $0.07 consensus, while revenue reached $387.5 million, ahead of estimates of $356.0 million and up 51.9% year over year. Reports said shares rose following the earnings release, supporting the view that demand for Carvykti and the company’s cell-therapy business remains strong. Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
  • Morgan Stanley issued a Buy rating: The bullish recommendation provides a counterweight to recent downgrades and may signal confidence in Legend’s commercial outlook and longer-term pipeline. Legend Biotech Receives a Buy from Morgan Stanley
  • Pipeline assets are becoming more important: Commentary highlighted Legend’s developing pipeline as a potential source of future growth beyond Carvykti, although these programs remain longer-term catalysts. Legend’s Pipeline Is Starting To Matter
  • Analyst targets remain widely dispersed: RBC maintained an Outperform rating with a $58 target, while Oppenheimer retained Market Perform at $40. A broader analyst compilation cited an average target of $55.29, indicating substantial perceived upside but also high uncertainty.
  • Leadership and competitive risks are pressuring sentiment: Oppenheimer downgraded Legend following the CEO’s departure, warning that increased competition could pressure the business. The former chief executive’s move to lead new biotech venture K2 Therapeutics may reinforce concerns about management continuity and talent retention. Legend Biotech Could See Pressures From Competition, CEO Transition, Oppenheimer Says
  • Several firms cut their targets: TD Cowen lowered its target to $24 and assigned Hold, while Oppenheimer reduced its target from $75 to $40. Although both targets remain above the current trading level, the magnitude of the cuts highlights deteriorating near-term expectations. Legend Biotech Downgraded at Oppenheimer
← Previous Stock of the DayNext Stock of the Day →

Recent News